Home » Stocks » BNR

Burning Rock Biotech Ltd. (BNR)

Stock Price: $34.30 USD 6.80 (24.73%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $35.20 +0.90 (2.62%) Jan 15, 7:56 PM
Market Cap 3.56B
Revenue (ttm) 56.81M
Net Income (ttm) -66.04M
Shares Out 103.80M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $34.30
Previous Close $27.50
Change ($) 6.80
Change (%) 24.73%
Day's Open 28.12
Day's Range 27.35 - 34.35
Day's Volume 1,088,620
52-Week Range 19.07 - 34.35

News

Hide News
Seeking Alpha - 2 weeks ago

Burning Rock Biotech went public in the U.S. in June 2020. The firm provides a range of early detection and therapy selection testing services in China.

Market Watch - 1 month ago

Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing...

Other stocks mentioned: OCX

About BNR

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 13 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen Plus that targets therapy ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
BNR
Full Company Profile

Analyst Forecasts

According to 3 analysts, the average rating for BNR stock is "Strong Buy." The 12-month stock price forecast is 31.92, which is a decrease of -6.94% from the latest price.

Price Target
$31.92
(-6.94% downside)
Analyst Consensus: Strong Buy